Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblix

Mer­ck is look­ing to fur­ther so­lid­i­fy its on­col­o­gy pipeline via a $6.7 bil­lion cash ac­qui­si­tion of Terns Phar­ma­ceu­ti­cals and its in­ves­ti­ga­tion­al treat­ment for chron­ic myeloid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.